Treatments for Parkinson disease-past achievements and current clinical needs

Neurology

Volumn 72, Issue 7 SUPPL. 2, 2009, Pages

  Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIHYDROERGOCRYPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; UNINDEXED DRUG; ADENOSINE A2 RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; BRAIN DEPTH STIMULATION; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DEMENTIA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSKINESIA; GOLD STANDARD; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SUBTHALAMIC NUCLEUS; BRAIN; DRUG ANTAGONISM; DRUG EFFECT; HISTORY; PATHOPHYSIOLOGY; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BRAIN; CHOLINESTERASE INHIBITORS; DEEP BRAIN STIMULATION; DOPAMINE AGONISTS; DYSKINESIAS; EXCITATORY AMINO ACID ANTAGONISTS; HISTORY, 20TH CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, ADENOSINE A2; SEROTONIN AGENTS;

EID: 61949226675     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31819908ce     Document Type: Article

References (75)

1. Ordenstein L. Sur la paralysie agitante et la sclérose en plaque generalisèe. Paris: Martinet; 1867.
2. Cooper IS. Relief of juvenile involuntary movement disorders by chemopallidectomy. JAMA 1957;164:1297-1301.
3. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958; 127:471.
4. Birkmayer W, Hornykiewicz O. The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wein Klin Wochenschr 1961;71:787-788.
5. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002;17:501-508.
6. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and the modification of parkonsonism. N Engl J Med 1967;276(7):374-379.
7. Schwab RS, Mador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;56:251-253.
8. Struppler A, Von UT. [Studies of mechanism of action of apormorphine on Parkinson's tremor.] Z Klin Med 1953; 152:46-57.
9. Shoulson I, Glaubiger GA, Chase TN. On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
10. Marsden CD, Parkes JD. "On-Off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
11. Lees AJ, Shaw KM, Stern GM. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet 1977;2:1034.
12. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
13. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
14. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984;107(Pt 2):487-506.
15. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265.
16. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-1136.
17. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
18. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
19. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol 2007;30: 295-300.
20. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19:426-432.
21. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkin son's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
22. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-520.
23. Bedard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19: 134-137.
24. Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
25. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
26. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149.
27. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
28. Manson AJ, Turner K, Lees AJ. Apomorphine mono-therapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
29. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
30. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125(Pt9):2058-2066.
31. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
32. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
33. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-2404.
34. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761-765.
35. Lewitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302.
36. Rascol O, Arnulf I, Peyro-Saint PH, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16:708-713.
37. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
38. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-883.
39. Samadi P, Gregoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-1051.
40. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936.
41. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-186.
42. Hassler R, Riechert T. [Indications and localization of stereotactic brain operations.] Nervenarzt 1954;25:441-447.
43. Ohye C, Kubota K, Hongo T, Nagao T, Narabayashi H. Ventrolateral and subventrolateral thalamic stimulation. Motor effects Arch Neurol 1964;11:427-434.
44. Benabid AL, Pollak P, Louveau A, Henry S, de RJ. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987;50:344-346.
45. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
46. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
47. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-707.
48. Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695-1705.
49. Voon V, Kubu C, Krack P, Houeto JL, Troster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006;21(Suppl 14):S305-S327.
50. Schupbach WM, Maltete D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68:267-271.
51. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007;130(Pt 6): 1596-1607.
52. Brundin P, Bjorklund A. Survival, growth and function of dopaminergic neurons grafted to the brain. Prog Brain Res 1987;71:293-308.
53. Freed WJ. Functional brain tissue transplantation: reversal of lesion-induced rotation by intraventricular substantia nigra and adrenal medulla grafts, with a note on intracranial retinal grafts. Biol Psychiatry 1983;18:1205-1267.
54. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996;19:102-109. Review.
55. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501-503.
56. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.
57. Stover NP, Bakay RA, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells at-tached to microcarriers in advanced Parkinson disease. Arch Neurol 2005;62:1833-1837.
58. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
59. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
60. Forno L. Pathology of Parkinson's Disease. In: Marsden C, Fahn S, eds. Movement Disorders. London: Butterworth International Medical Reviews; 1982:25-40.
61. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
62. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
63. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl 4):S1-S166.
64. Shoulson I. Where do we stand on neuroprotection? Where do we go from here? Mov Disord 1998;13(Suppl 1):46-48.
65. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-2301.
66. Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Adv Neurol 1996;69:427-431.
67. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119(Pt 2):585-591.
68. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-582.
69. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
70. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
71. Zimprich A, Muller-Myhsok B, Farrer M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004;74: 11-19.
72. Abbott A. Trials offer way forward for Parkinson's. Nature 2001;410:401.
73. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
74. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-1031.
75. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17.